BIONANO GENOMICS INC (BNGO)

3 Contrarian Investments to Make Now for Massive Upside Potential

A combination of nervous investors and highly aggressive short sellers has made many contrarian investments quite attractive. 

Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing

Researchers used optical genome mapping in addition to whole genome sequencing in pediatric leukemia samples and identified additional structural...

Bionano Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Bionano Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules...

Bionano Announces Publication Showing that OGM Identifies Genetic Aberrations in Sarcoma Samples that May Lead to Improved Diagnosis but were Missed by Classical Cytogenetics

A peer-reviewed study compared optical genome mapping (OGM) to classical cytogenetic techniques used for analysis of solid tumor cancer samples. ...

Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Including Live Product Showcase Featuring the Company’s New Stratys™ System

Bionano will host a pre-conference scientific session that will include a live product demonstration of the Stratys™ system for high throughput optical...

Bionano Genomics (BNGO) Q4 2023 Earnings Call Transcript

BNGO earnings call for the period ending December 31, 2023.

BNGO Stock Earnings: Bionano Genomics Misses EPS, Beats Revenue for Q4 2023

BNGO stock results show that Bionano Genomics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

BNGO Stock Earnings: Bionano Genomics Misses EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bionano Genomics (NASDAQ:BNGO) just reported results for the fourth quarter of ...

Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024

Q4 2023 revenue was $10.7 million, which represents a 30% increase over Q4 2022FY 2023 revenue was $36.1 million, which represents a 30% increase over FY...

Bionano to Present at TD Cowen’s 44th Annual Health Care Conference

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief...

Bionano to Report Fourth Quarter and Year End 2023 Financial Results and Host a Conference Call and Webcast on March 5, 2024

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast...

Bionano Announces Amendment to Debt Financing Arrangement to Extend Cash Runway

- Amendment Reduces Bionano’s Outstanding Debt -...

7 Penny Stocks to Buy on the Dip: February 2024

With the markets turning lower, these penny stocks to buy stand out as attractive options. Consider these seven stocks.

7 Penny Stocks to Buy on the Dip: February 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Now might be a good time to consider scooping up shares of penny stocks to buy ...

Bionano to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference

SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief...

Bionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing

Pre-print publication from Levy, et al. describes the second phase of a multisite evaluation and validation of optical genome mapping (OGM) that is...

Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications

26 different customers representing North America, Asia and Europe33 oral presentations across four consecutive days69 scientific posters will be featured...

Contrarian Kings: 3 Unloved Stocks That Could Be the Next Market Darlings

These excellent contrarian stock picks are well-positioned to benefit from huge trends and are likely to be very profitable for investors. 

Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care (SOC) in Genetic Disease Testing

Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care (SOC) in Genetic Disease Testing ...

Bionano Genomics expects Q4 revenue growth of 27% to 30% (NASDAQ:BNGO)

Bionano Genomics expects Q4 revenue of $10.4M to $10.7M, a 27% to 30% growth YoY.

Bionano Reports Preliminary Fourth Quarter and Full-Year 2023 Results

Preliminary Q4 2023 revenue expected to be between $10.4 and $10.7 million, which would represent an estimated increase of 27% to 30% over Q4 2022Reached...

International Consortium Publishes Comprehensive Roadmap for the Clinical Implementation of OGM in Hematological Malignancy Applications

Framework was co-authored by an international consortium made up of 18 cancer researchers Publication includes researchers’ recommendations for...

OGM Added to International System for Human Cytogenomic Nomenclature

SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced a publication outlining the addition of optical...

Bionano Announces Significant Upgrades to its Bionano Solve Pipeline and its VIA™ Software for OGM Data Analysis in Constitutional Genetic Disease Research

SAN DIEGO, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced significant upgrades to its pipeline for analysis of...

Bionano Announces Publication of Largest Prospective Prenatal Study Comparing OGM to Chromosomal Microarray Analysis and Karyotyping

Key findings from prospective evaluation of 200 prenatal samples: Optical genome mapping (OGM) detected pathogenic structural variants (SVs) in 20.5% of...

Cancers Journal Publishes Special Issue Dedicated to OGM’s Impact on Hematological Malignancy Research

SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a special issue of Cancers journal...

Study Shows that OGM Plays an Important Role in Efficient Diagnosis of FSHD

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication by scientists at Revvity Omics (formerly Perkin Elmer...

Bionano Announces Publication Demonstrating Utility of OGM to Assess Genome Integrity of CRISPR-Edited Cells as Part of Gene Therapy Development

SAN DIEGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication demonstrating the use of optical genome...

LeddarTech Appoints Chris Stewart as Chief Financial Officer

Bionano Announces Presentation of OGM Utility Across Key Research Applications at the Association for Molecular Pathology Annual Meeting

A corporate workshop session will feature Dr. Alka Chaubey, Bionano’s chief medical officer, Dr. Panieh Terraf from Memorial Sloan Kettering Cancer Center,...

3 Stocks That Are Poised to Generate Outsized Returns

The Street is greatly underestimating the potential of these three names, making them wonderful stocks to buy for big returns. 

Bionano Genomics (BNGO) Q3 2023 Earnings Call Transcript

BNGO earnings call for the period ending September 30, 2023.

Bionano Reports Third Quarter 2023 Results and Highlights Recent Business Progress

Q3 2023 revenue was $9.3 million, which represents a 29% increase over Q3 2022Installed base of Saphyr® systems totaled 301 as of September 30, 2023, which...

Bionano to Report Third Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 8, 2023

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast...

3 Deeply Undervalued Growth Stocks

As in 2022, the current downturn of stocks appears to be way overdone, making this a good time to buy undervalued growth stocks.